Evaluating non-invasive methods for diagnosing chronic liver disease
Official title: Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease. a Retrospective and Prospective 20-year Follow-up.
Run by Association HGE CHU Bordeaux Sud · NCT02060565 · Data updated 2026-11-12
This study is trying to see if non-invasive tests can help predict how well people with chronic liver disease will do over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Association HGE CHU Bordeaux Sud Academic / other |
| Locations | 1 site (Pessac) |
| Status | Recruiting |
| Started | February 2014 |
| Main results expected | January 2030 |
| Study ends | February 2034 |
| Registry record updated | July 20, 2023 |
| Trial ID | NCT02060565 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with chronic hepatitis C, chronic hepatitis B, alcohol liver disease, or non-alcoholic liver disease.
✕Probably not a fit
Patients with ascites will not benefit from this study as they are excluded from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the long-term prognosis value of non-invasive diagnostic methods for chronic liver disease over a 20-year period. It will follow patients diagnosed with chronic liver conditions, including hepatitis C, hepatitis B, alcohol-related liver disease, and non-alcoholic liver disease. The study will analyze how these methods can predict survival rates and complications associated with cirrhosis. Both retrospective and prospective data will be collected to provide a comprehensive understanding of the disease progression.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of diagnosing chronic liver disease and enhance patient management strategies.
How similar studies have gone: Other studies have shown promise in using non-invasive methods for diagnosing liver diseases, indicating that this approach is gaining traction in the medical field.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * chronic hepatitis C * chronic hepatitis B * alcohol liver disease * non alcoholic liver disease Exclusion Criteria: * ascitis
Where it's running
-
Centre d'Investigation de la Fibrose hépatique Service Hépato-Gastroentérologie Hopital Haut-Lévèque
Pessac, France Recruiting
Study contacts
- Study coordinator: Victor de Lédinghen, MD, PhD
- Email: victor.deledinghen@chu-bordeaux.fr
- Phone: 0033557656439
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Copper supplementation for people with cirrhosis
This trial will try giving copper supplements to adults with cirrhosis who have low copper levels or signs of copper deficiency to see if liver-related health improves.
-
Understanding how chronic liver disease patients with organ failure fare after non‑emergency hospital stays
This study follows adults with chronic liver disease who are admitted to the hospital non-electively to see how their condition develops over six months when liver and/or other organs fail.
-
Understanding social and health needs of people with chronic liver disease in outpatient care
This project will see how common social needs are and whether adults with chronic liver disease want their outpatient providers to help with them.
-
Using rifaximin to improve liver transplant outcomes
This study is testing if taking the antibiotic rifaximin before and after liver transplant surgery can help prevent early problems with the new liver in adults.
-
Endoscopic ultrasound shear wave elastography for measuring liver fibrosis
This study will test whether endoscopic ultrasound shear wave elastography and attenuation imaging can estimate liver fibrosis compared with biopsy and FibroScan in adults with suspected MASLD or MASH.
-
Comparing intravenous and under-skin LAENNEC for alcoholic and non-alcoholic fatty liver disease
This will test whether 10 ml intravenous LAENNEC given twice weekly for six weeks works better and is as safe as 4 ml subcutaneous LAENNEC in adults 19–70 with alcoholic or non‑alcoholic fatty liver disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.